Skip to main content

Market Overview

Europe Approves AbbVie's Skyrizi For Second Indication

Europe Approves AbbVie's Skyrizi For Second Indication
  • The European Commission (EC) has approved AbbVie Inc's (NYSE: ABBV) Skyrizi (risankizumab) 150 mg subcutaneous injection for psoriatic arthritis in adults.
  • The approval covers Skyrizi alone or combined with methotrexate (MTX) for active psoriatic arthritis in adults who have had an inadequate response or have been intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). 
  • The approval marks the second indication for Skyrizi.
  • Related Link: AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis.
  • Skyrizi collaborates with Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
  • Skyrizi is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23, a cytokine involved in inflammatory processes.
  • Price Action: ABBV shares are up 0.26% at $116.72 during the market session on the last check Wednesday.

Related Articles (ABBV)

View Comments and Join the Discussion!

Posted-In: Arthritis BriefsBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at